Show simple item record

dc.contributor.authorSalinas-Montalvo, Ana María
dc.contributor.authorSupramaniam, Aroon
dc.contributor.authorMcMillan, Nigel AJ
dc.contributor.authorIdris, Adi
dc.date.accessioned2021-10-20T03:36:19Z
dc.date.available2021-10-20T03:36:19Z
dc.date.issued2021
dc.identifier.issn0304-3835
dc.identifier.doi10.1016/j.canlet.2021.10.005
dc.identifier.urihttp://hdl.handle.net/10072/409247
dc.description.abstractWhile platinum-based chemotherapy, radiation therapy and or surgery are effective in reducing human papillomavirus (HPV) driven cancer tumours, they have some significant drawbacks, including low specificity for tumour, toxicity, and severe adverse effects. Though current therapies for HPV-driven cancers are effective, severe late toxicity associated with current treatments contributes to the deterioration of patient quality of life. This warrants the need for novel therapies for HPV derived cancers. In this short review, we examined RNA-based therapies targeting the major HPV oncogenes, including short-interfering RNAs (siRNAs) and clustered regularly interspaced short palindromic repeats (CRISPR) as putative treatment modalities. We also explore other potential RNA-based targeting approaches such as microRNAs (miRNAs), long non-coding RNAs (lncRNAs), and mRNA vaccines as future treatment modalities for HPV cancers. Some of these technologies have already been approved for clinical use for a range of other human diseases but not for HPV cancers. Here we explore the emerging evidence supporting the effectiveness of some of these gene-based therapies for HPV malignancies. In short, the evidence sheds promising light on the feasibility of translating these technologies into a clinically relevant treatment modality for HPV derived cancers and potentially other virally driven human cancers.
dc.description.peerreviewedYes
dc.languageen
dc.publisherElsevier BV
dc.relation.ispartofpagefrom111
dc.relation.ispartofpageto120
dc.relation.ispartofjournalCancer Letters
dc.relation.ispartofvolume523
dc.subject.fieldofresearchOncology and carcinogenesis
dc.subject.fieldofresearchcode3211
dc.titleRNA-based gene targeting therapies for human papillomavirus driven cancers
dc.typeJournal article
dc.type.descriptionC1 - Articles
dcterms.bibliographicCitationSalinas-Montalvo, AM; Supramaniam, A; McMillan, NAJ; Idris, A, RNA-based gene targeting therapies for human papillomavirus driven cancers, Cancer Letters, 2021, 523, pp. 111-120
dcterms.licensehttps://creativecommons.org/licenses/by-nc-nd/4.0/
dc.date.updated2021-10-13T02:35:11Z
dc.description.versionAccepted Manuscript (AM)
gro.rights.copyright© 2021 Elsevier Ireland. Published by Elsevier Ltd. Licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International Licence (http://creativecommons.org/licenses/by-nc-nd/4.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, providing that the work is properly cited.
gro.hasfulltextFull Text
gro.griffith.authorIdris, Adi
gro.griffith.authorMcMillan, Nigel
gro.griffith.authorSalinas Montalvo, Ana Maria M.
gro.griffith.authorSupramaniam, Aroon


Files in this item

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record